

**CLAIM LISTING**

1. (Currently Amended) A composition for delivering an agent to a ~~target~~ neoplastic cell of a solid tumor expressing a neoplasm-specific antigen, comprising:
  - (a) [a] an attenuated Salmonella microorganism that has, on its [cell] surface, at least one ~~exogenous molecule~~ antibody or fragment thereof that binds to [an] a neoplasm-specific antigen on the surface of a ~~target~~ neoplastic cell of a solid tumor; and
  - (b) an agent.
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Currently Amended) The composition of ~~claim 4~~ claim 1, wherein the Salmonella is Salmonella typhimurium VNP20009 or Salmonella typhimurium SL7207.
6. (Currently Amended) The composition of claim 1, wherein the ~~microorganism~~ Salmonella expresses the ~~exogenous molecule~~ antibody or fragment thereof.
7. (Currently Amended) The composition of claim 6, wherein the ~~microorganism~~ Salmonella transiently expresses the ~~exogenous molecule~~ antibody or fragment thereof.
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Currently Amended) The composition of ~~claim 10~~ claim 1, wherein the antibody is a mammalian antibody.

12. (Original) The composition of claim 11, wherein the antibody is a human antibody.
13. (Currently Amended) The composition of ~~claim 10~~ claim 1, wherein the antibody is a chimeric antibody.
14. (Original) The composition of claim 13, wherein the chimeric antibody is a humanized antibody.
15. (Currently Amended) The composition of ~~claim 10~~ claim 1, wherein the antibody is a single-chain antibody.
16. (Cancelled)
17. (Cancelled)
18. (Currently Amended) The composition of ~~claim 17~~ claim 1, wherein the solid-tumor [cell] is a colon-tumor [cell].
19. (Currently Amended) The composition of ~~claim 16~~ claim 1, wherein the neoplastic cell is a carcinoembryonic-antigen- (CEA)-expressing cell.
20. (Currently Amended) The composition of ~~claim 19~~ claim 1, wherein the ~~CEA-expressing~~ neoplastic cell is selected from the group consisting of a bowel cancer cell, a breast cancer cell, a cervical cancer cell, a colon cancer cell, an esophageal cancer cell, a head cancer cell, a liver cancer cell, a lung cancer cell, a neck cancer cell, an ovarian cancer cell, a pancreatic cancer cell, and a stomach cancer cell.
21. (Currently Amended) The composition of ~~claim 20~~ claim 19, wherein the CEA-expressing cell is a colon cancer cell.
22. (Cancelled)
23. (Currently Amended) The composition of ~~claim 16~~ claim 1, wherein the antigen is selected from the group consisting of CAK1, CDK4, CDR2, carcinoembryonic antigen

- (CEA), disialoganglioside GD2, HER-2, large external antigen (LEA), MAGEs, MUC1, p21, podocalyxin, Ras, UK114, and WT1.
24. (Original) The composition of claim 23, wherein the antigen is a CEA.
25. (Original) The composition of claim 1, wherein the agent is selected from the group consisting of a diagnostic agent, a labelling agent, a preventive agent, and a therapeutic agent.
26. (Currently Amended) The composition of ~~claim 25~~ claim 1, wherein the ~~therapeutic agent is selected from the group consisting of~~ comprises an anti-tumor compound, ~~a lipid, a nucleic acid, a polypeptide, a polysaccharide, and a pro-drug or a pro-drug of an anti-tumor compound.~~
27. (Currently Amended) The composition of claim 26, wherein the nucleic acid ~~is a plasmid~~ comprises a plasmid encoding a polypeptide selected from the group consisting of an anti-proliferation factor, an immuno-enhancing factor, a pro-apoptotic factor, and a pro-drug converting enzyme.
28. (Cancelled)
29. (Currently Amended) The composition of ~~claim 27~~ claim 26, wherein the nucleic acid comprises a plasmid comprising at least one gene silencing cassette ~~plasmid is an expression plasmid.~~
30. (Cancelled)
31. (Cancelled)
32. (Cancelled)
33. (Currently Amended) A method for treating neoplasia in a subject in need of treatment, the method comprising:

- a) administering to the subject a therapeutic composition in an amount effective to treat the neoplasia, wherein the therapeutic composition comprises:
    - i. [a] an attenuated Salmonella microorganism that has, on its ~~cell~~ surface, at least one ~~exogenous molecule~~ antibody or fragment thereof that binds to [an] a neoplasm-specific antigen on the surface of a neoplastic cell of a solid tumor in the subject; and
    - ii. a therapeutic agent;
  - b) binding of the attenuated Salmonella to the neoplastic cell; and
  - c) infecting the neoplastic cell.
34. (Cancelled)
35. (Currently Amended ) The method of ~~claim 34~~ claim 33, wherein the solid tumor is a colon tumor.
36. (Currently Amended) The method of ~~claim 35~~ claim 33, wherein the solid tumor expresses carcinoembryonic antigen (CEA).
37. (Currently Amended) The method of ~~claim 36~~ claim 33, wherein the solid tumor is selected from the group consisting of a bowel tumor, a breast tumor, a cervical tumor, a colon tumor, an esophageal tumor, a head tumor, a liver tumor, a lung tumor, a neck tumor, an ovarian tumor, a pancreatic tumor, and a stomach tumor.
38. (Cancelled)
39. (Cancelled)
40. (Cancelled)
41. (Cancelled)

42. (Currently Amended) The method of ~~claim 41~~ claim 33, wherein the *Salmonella* is *Salmonella typhimurium* VNP20009 or *Salmonella typhimurium* SL7207.
43. (Currently Amended) The composition of claim 33, wherein the ~~microorganism~~ *Salmonella* expresses the ~~exogenous molecule~~ antibody or fragment thereof.
44. (Currently Amended) The composition of claim 43, wherein the ~~microorganism~~ *Salmonella* transiently expresses the ~~exogenous molecule~~ antibody or fragment thereof.
45. (Cancelled)
46. (Cancelled)
47. (Cancelled)
48. (Currently Amended) The method of ~~claim 47~~ claim 33, wherein the antibody is a mammalian antibody.
49. (Original) The method of claim 48, wherein the antibody is a human antibody.
50. (Currently Amended) The method of ~~claim 47~~ claim 33, wherein the antibody is a chimeric antibody.
51. (Original) The method of claim 50, wherein the chimeric antibody is a humanized antibody.
52. (Currently Amended) The method of ~~claim 47~~ claim 33, wherein the antibody is a single-chain antibody.
53. (Cancelled)
54. (Original) The method of claim 33, wherein the antigen is selected from the group consisting of CAK1, CDK4, CDR2, carcinoembryonic antigen (CEA), disialoganglioside GD2, HER-2, large external antigen (LEA), MAGEs, MUC1, p21, podocalyxin, Ras, UK114, and WT1.

55. (Original) The method of claim 54, wherein the antigen is a CEA.
56. (Currently Amended) The method of claim 33, wherein the therapeutic agent ~~is selected from the group consisting of~~ comprises an anti-tumor compound, ~~a lipid, a nucleic acid, a polypeptide, a polysaccharide, and a pro-drug or a pro-drug converting enzyme of an anti-tumor compound.~~
57. (Cancelled)
58. (Cancelled)
59. (Cancelled)
60. (Currently Amended) The composition of ~~claim 57~~ claim 56, wherein the nucleic acid comprises a plasmid comprising at least one gene silencing cassette ~~plasmid is an expression plasmid.~~
61. (Cancelled)
62. (Cancelled)
63. (Cancelled)
64. (Cancelled)
65. (Currently Amended) A method for treating neoplasia in a subject in need of treatment, the method comprising:
- a) administering to the subject a therapeutic composition in an amount effective to treat the neoplasia, wherein the therapeutic composition ~~consists of~~ comprises [a] an attenuated Salmonella microorganism that has, on its cell surface, at least one ~~exogenous molecule~~ antibody or fragment thereof that binds to [an] a neoplasm- specific antigen on the surface of a neoplastic cell of a solid tumor in the subject;

- b) binding of the attenuated *Salmonella* to the neoplastic cell; and
- c) infecting the neoplastic cell.